The downregulation of TRPM2 levels resulted in an elevation in intracellular reactive oxygen species (ROS) levels, indicating that TRPM2 may have enhanced ovarian cancer cell activity by inhibiting ROS (Figure 7H). This evidence concerns the gene TRPM2 and ovarian carcinoma.